I. Transaction Overview
Jiangsu Dongxing Smart Medical Technology Co., Ltd. (hereinafter referred to as "the Company" or "the Listed Company") intends to acquire 90% of the equity of Wuhan Yijiaobao Biological Materials Co., Ltd. (hereinafter referred to as "Wuhan Yijiaobao" or "the Target Company") for cash (hereinafter referred to as "this transaction"). If successfully implemented, Wuhan Yijiaobao will become a controlling subsidiary of the Company. According to preliminary research and calculations, this transaction is expected to constitute a major asset restructuring as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies." This transaction does not involve the issuance of shares by the listed company, does not constitute a related party transaction, and will not lead to changes in the controlling shareholder or actual controller of the listed company. The Company will fulfill relevant procedures and prepare and disclose related documents in accordance with relevant regulations. For specific details, please refer to the Company's announcement on September 26, 2025, titled "Announcement on Planning Major Asset Restructuring and Signing the 'Equity Acquisition Intent Agreement'" (Announcement No. 2025-042).